| Literature DB >> 29474069 |
Ming-Hao Hu1,2, Yu-Qing Wang1, Ze-Yi Yu1, Lu-Ni Hu1, Tian-Miao Ou1, Shuo-Bin Chen1, Zhi-Shu Huang1, Jia-Heng Tan1.
Abstract
Downregulating transcription of the oncogene c-MYC is a feasible strategy for cancer therapy. Stabilization of the G-quadruplex structure present in the c-MYC promoter can suppress c-MYC transcription. Thus, far, several ligands targeting this structure have been developed. However, most have shown no selectivity for the c-MYC G-quadruplex over other G-quadruplexes, leading to uncertain side effects. In this study, through structural modification of aryl-substituted imidazole/carbazole conjugates, a brand-new, four-leaf clover-like ligand called IZCZ-3 was found to preferentially bind and stabilize the c-MYC G-quadruplex. Further intracellular studies indicated that IZCZ-3 provoked cell cycle arrest and apoptosis and thus inhibited cell growth, primarily by blocking c-MYC transcription through specific targeting of the promoter G-quadruplex structure. Notably, IZCZ-3 effectively suppressed tumor growth in a mouse xenograft model. Accordingly, this work provides an encouraging example of a selective small molecule that can target one particular G-quadruplex structure, and the selective ligand might serve as an excellent anticancer agent.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29474069 DOI: 10.1021/acs.jmedchem.7b01697
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446